トップ研究者を探すがん抑制性ニッチの実態とその誘導による新規治療法の開発

がん抑制性ニッチの実態とその誘導による新規治療法の開発

KAKEN 科学研究費助成事業データベース で見る
研究課題番号 KAKENHI-PROJECT-16K18420
研究種目 若手研究(B)
研究分野 生物系
総合生物
腫瘍学
腫瘍生物学
研究機関 徳島大学
代表研究者 中村 信元
研究期間 開始年月日 2016/4/1
研究期間 終了年度 2017
研究ステータス 完了 (2017/4/1)
配分額(合計) 3,640,000 (直接経費 :2,800,000、間接経費 :840,000)
配分額(履歴) 2017年度:1,820,000 (直接経費 :1,400,000、間接経費 :420,000)
2016年度:1,820,000 (直接経費 :1,400,000、間接経費 :420,000)
キーワード multiple myeloma
osteoblast
Pim-2
PGC-1α
AMPK
mature osteoblast
pim-2
PGC-1
成熟骨芽細胞
ミトコンドリア
がん抑制性ニッチ
酸性環境

研究成果

[雑誌論文] Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome

Nakamura Shingen、Azuma Momoyo、Maruhashi Tomoko、Sogabe Kimiko、Sumitani Ryohei、Uemura Munenori、Iwasa Masami、Fujii Shiro、Miki Hirokazu、Kagawa Kumiko、Hiraga Takashi、Kondo Noriyasu、Fujita Hiromi、Mahara Fumihiko、Abe Masahiro 2018

[雑誌論文] Multiple myeloma with high adenosine deaminase expression

Shingen NAKAMURA, Hirokazu MIKI, Masami IWASA, Akishige IKEGAME,Tomoko MARUHASHI, Ryohei SUMITANI, Munenori UEMURA, Mamiko TAKAHASHI,Asuka ODA, Shiro FUJII, Kumiko KAGAWA and Masahiro ABE 2017

[学会発表] Mature osteoblasts reduce Pim-2 to cause an energy crisis in myeloma cells

Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Keiichiro Watanabe, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Masahiro Abe 2017

[学会発表] Restoration of bone formation induces an energy crisis in myeloma cells

Ryota Amachi, Shingen Nakamura, Hirokazu Miki, ,Hirofumi Tenshin, Keiichiro Watanabe, Jumpei Teramachi, Asuka Oda, Masami Iwasa, Shiro Fujii,Kumiko Kagawa, Masahiro Abe 2017

[学会発表] Osteoblast creates a non-permissive niche for myeloma

Ryota Amachi, Masahiro Hiasa , Jumpei Teramachi, Asuka Oda, Ariunzaya Bat-Erdene, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiro Fujii, Eiji Tanaka , Toshio Matsumoto , Masahiro Abe 2017

[学会発表] Mature osteoblasts reduce Pim-2 to cause an energy crisis in myeloma cells

Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Keiichiro Watanabe, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Masahiro Abe 2017

[雑誌論文] Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.

Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, Tenshin H, Iwasa M, Fujii S, Kagawa K, Miki H, Kurahashi K, Yoshida S, Endo I, Haneji T, Matsumoto T, Abe M. 2017

[雑誌論文] Primary CD30-positive Diffuse Large B-cell Lymphoma in the Superior Vena Cava

Nakamura S, Kagawa K, Sumitani R, Uemura M, Takahashi M, Iwasa M, Fujii S, Miki H, Abe M 2017

[雑誌論文] Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions

Nakamura S, Miki H, Oda A, Amachi R, Teramachi J, Sogabe K, Fujino H, Maruhashi T, Fujii S, Kagawa K , Abe M 2016

[雑誌論文] A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.

Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, Hanson D, Watanabe K, Fujii S, Miki H, Kagawa K, Iwasa M, Endo I, Kondo T, Yoshida S, Aihara KI, Kurahashi K, Kuroda Y, Horikawa H, Tanaka E, Matsumoto T, Abe M. 2016

[学会発表] Creation of a non-permissive niche for myeloma by bone formation

Ryota Amachi, Jumpei Teramachi,Masahiro Hiasa,Takeshi Harada,Asuka Oda,Shingen Nakamura,Keiichiro Watanabe,Shiro Fujii,Hirokazu Miki,Kumiko Kagawa,Itsuro Endo,Eiji Tanaka,Toshio Matsumoto,Masahiro Abe 2016

[学会発表] Alteration of Pim-2 synthesis and degradation in myeloma cells by anti-myeloma agents.

Shingen Nakamura, Hirokazu Miki, Ariunzaya BAT-ERDENE,Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Asuka Oda, Masami Iwasa, Shiro Fujii,Kumiko Kagawa, Masahiro Abe 2016